Grifols SA ADR
Yahoo Finance • 2 months ago
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
GigaGen, Inc. The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s recombinant polyclonals are p... Full story
Yahoo Finance • 7 months ago
Grifols 2023 Annual Report on Form 20-F filed with the SEC
BARCELONA, Spain, April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Rep... Full story
Yahoo Finance • 9 months ago
Charles Brandes Bolsters Portfolio with a Strategic Emphasis on Corteva Inc
Insight into the Investment Moves of a Value Investing Stalwart Charles Brandes (Trades, Portfolio), a seasoned value investor and founder of Brandes Investment Partners, has made notable changes to his investment portfolio in the fourth... Full story
Yahoo Finance • 10 months ago
Grifols Sues in NY Over Gotham City Short-Seller Report
(Bloomberg) -- Grifols SA sued Gotham City Research over a report alleging the company has overstated profit and misstated its accounting. Most Read from Bloomberg Putin Sends US Signal on Ukraine Talks, Seeing War Advantage One of World... Full story
Yahoo Finance • 10 months ago
Grifols sees no impact from Gotham report on China stake sale
BARCELONA (Reuters) -Spanish pharma company Grifols sees no problem closing the sale of a stake in Shanghai RAAS despite the market impact of a negative report by Gotham City Research that questioned its accounting, which Grifols top brass... Full story
Yahoo Finance • 10 months ago
Factbox-What does the Gotham City report say about Grifols?
By Nell Mackenzie LONDON (Reuters) - Shares in Grifols fell as much as over 40% on Tuesday, wiping $3.83 billion off its market value, after hedge fund Gotham City Research questioned its accounting, prompting the Spanish drugmaker to "ca... Full story
Yahoo Finance • last year
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Grifols, S.A. Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenous This first in... Full story
Yahoo Finance • last year
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) GigaGen anticipates trial initiation in 2024 GIGA-564 is a differen... Full story
Yahoo Finance • last year
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript November 2, 2023 Nuria Pascual: Hello, everyone, and welcome to the Grifols Third Quarter 2023 Conference Call. Thank you very much for taking the time to join us today. This is... Full story
Yahoo Finance • last year
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's patientsABvac40 treatment slowed disease progression up to 38% compared with placebo as m... Full story
Yahoo Finance • last year
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary... Full story
Yahoo Finance • last year
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated wit... Full story
Yahoo Finance • last year
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency
Grifols, S.A. Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin®-C (Alpha1-Proteinase Inhibitor [Human]) to slow emphysem... Full story
Yahoo Finance • 2 years ago
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
Grifols, S.A. Now available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home withou... Full story
Yahoo Finance • 2 years ago
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and... Full story
Yahoo Finance • 2 years ago
10 Best Medical Stocks Under $10
In this article, we will discuss the 10 best medical stocks under $10. To skip our detailed analysis of the healthcare sector, go directly to the 5 Best Medical Stocks Under $10. According to the Centers for Medicare and Medicaid Services... Full story
Yahoo Finance • 2 years ago
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary... Full story
Yahoo Finance • 2 years ago
Grifols Procleix Plasmodium Assay receives CE mark, a first for malaria blood screening
Procleix Plasmodium Assay is a nucleic acid test (NAT) that detects the presence of Plasmodium, a protozoan parasite that causes malaria worldwide and creates a significant risk for both blood safety and availability Screening blood donors... Full story
Yahoo Finance • 3 years ago
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary o... Full story
Yahoo Finance • 3 years ago
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022
Virtual Investor Conferences DB DB Logo NEW YORK, May 08, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, May 10 and Wednesday, May 11, featu... Full story
